ClinicalTrials.gg
Active, not recruitingNCT07855432C REACTIVE PROUpdated Oct 2, 2026

THE EFFECT OF CRP/LYMPHOCYTE AND NEUTROPHIL/LYMPHOCYTE RATIOS ON LENGTH OF HOSPITAL STAY AND MORTALITY IN PATIENTS ADMITTED TO THE BURN UNIT

An observational study in Burn, sponsored by Samsun University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Samsun University · Observational

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Burns with a site in Turkey — 13 open to participants now, 17 under way, none of them phase 3. Burns · Turkey.

Planned enrollment
2nd of 10
500 · median 97
Started
2020
with 3 others
Observational
10 of 43
2 open now
Primary completion
2025-12
later than 5 of 16 live
Registered
41st of 43
by date
Lead sponsor
2 of 43
Samsun University

Among the 43 studies in Burns with a site in Turkey, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2020, is one of 10 observational ones, reaches primary completion later than 5 of the 16 other live ones, and was the 41st registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

13 of the 43 studies in Burns with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Burns with a site in Turkey, or all of them as a file.
02

Study summary

This retrospective study aims to evaluate the prognostic value of systemic inflammatory markers, specifically the C-reactive protein-to-lymphocyte ratio (CLR) and neutrophil-to-lymphocyte ratio (NLR), in patients admitted to the burn intensive care unit. Burn injury triggers a profound systemic inflammatory response, which significantly influences clinical outcomes. By analyzing medical records, the study investigates whether admission or dynamic changes in CLR and NLR correlate with the length of hospital stay (LOS) and in-hospital mortality. The ultimate goal is to identify cost-effective, readily available biomarkers for early risk stratification in severe burn management.

Read the detailed description

Severe burn injuries induce a complex pathophysiology characterized by extensive tissue damage, systemic inflammation, hypermetabolism, and immune dysregulation. Early assessment of disease severity and risk stratification is critical for optimizing treatment strategies and improving patient survival in burn units. Traditional scoring systems often require multiple parameters, whereas routine complete blood counts and inflammatory markers offer rapid, cost-effective alternatives.

This retrospective observational cohort study evaluates the clinical utility of the C-reactive protein-to-lymphocyte ratio (CLR) and the neutrophil-to-lymphocyte ratio (NLR) as prognostic indicators in adult patients treated in the burn intensive care unit.

Study Objectives:

Primary Objective: To evaluate the association between admission CLR and NLR values and overall in-hospital mortality among burn unit patients.

Secondary Objective: To determine the relationship between initial/longitudinal CLR and NLR dynamics and the total length of hospital stay (LOS), length of ICU stay, and complication rates (e.g., sepsis, acute kidney injury).

Methodology:

Patient data will be extracted retrospectively from hospital electronic medical records. Laboratory parameters-including complete blood count (neutrophil and lymphocyte counts) and C-reactive protein (CRP) levels measured upon admission (and at predefined intervals, if applicable)-will be recorded to calculate CLR and NLR values. Demographic data (age, sex), clinical variables (total body surface area burned [TBSA], burn depth, inhalation injury status, etiology of burn) and clinical outcomes (LOS and mortality) will be documented.

03

Conditions studied

  • Burn

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients (aged 18 years and older) who were admitted to the Burn Intensive Care Unit (BICU) of Samsun Training and Research Hospital between January 2020 and December 2025. Patient data will be extracted retrospectively from electronic medical records. Eligible participants are those with confirmed acute burn injuries whose routine laboratory investigations (complete blood count and C-reactive protein) were performed upon admission.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with missing data
  • Patients with chronic inflammatory disease (optional)
  • Pediatric patients under 18 years of age
  • Patients with a hospital stay of less than one day

Exclusion criteria

Exclusion Criteria:

  • Patients with missing data
  • Patients with chronic inflammatory disease (optional)
  • Pediatric patients under 18 years of age
  • Patients with a hospital stay of less than one day
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Burn Unit Patients

    Adult patients (≥18 years) admitted to the burn intensive care unit whose medical records, including complete blood counts and CRP levels, are evaluated retrospectively.

    Other: Routine blood samples collected for CRP, neutrophil, and lymphocyte counts during ICU admission.

Interventions

  • OtherRoutine blood samples collected for CRP, neutrophil, and lymphocyte counts during ICU admission.

    Routinely checked complete blood count and biochemistry tests

06

What researchers measure

Primary outcomes

  1. In-Hospital Mortality

    Evaluation of the association between baseline CRP/lymphocyte ratio (CLR) and neutrophil/lymphocyte ratio (NLR) values upon admission and the occurrence of all-cause in-hospital mortality.

    Time frame: 01.01.2020 - 31.12.2025

07

Study locations

1 site
08

References and documents

Publications

  • Pao-Jen Kuo, Ching-Ya Huang, Kuan-Hao Liao, Ching-Hua Tsai, Wei-Ti Su, Shiun-Yuan Hsu, Ching-Hua Hsieh. Association of C-reactive protein-to-lymphocyte ratio and mortality outcome in patients with trauma admitted to an intensive care unit. Signa Vitae. 2026; 22(2): 96-103. doi: 10.22514/sv.2025.183

Individual participant data

Plan to share: No — No information will be shared, in order to protect the patient's personal data.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Dec 2025, 71 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Jan 1, 2020
Primary completionActual
Dec 31, 2025
CompletionEst.
Sep 30, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855432
Lead sponsor
Samsun University
Responsible party
Hatice Bahadır Altun (Specialist Doctor, Samsun University) — Principal investigator
First posted
Oct 2, 2026
Start date
Jan 1, 2020
Primary completion
Dec 31, 2025
Completion
Sep 30, 2026 (estimated)
Last update
Oct 2, 2026

Study contacts

Hatice Bahadır Altun
principal investigator · SAMSUN UNIVERSITESI

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion